Overview
- The Charité treated a 19-year-old man with severe beta‑thalassemia by infusing ex vivo CRISPR‑edited stem cells on May 28, 2026, marking the first use of the therapy in routine care in Germany.
- Doctors harvested the patient’s hematopoietic stem cells, sent them to a manufacturing lab in the Netherlands for CRISPR activation of fetal (gamma) globin, and reinfused more than 900 million edited cells after myeloablative chemotherapy conditioning.
- Within about 40 days the patient’s body began producing normal levels of hemoglobin, he became transfusion-independent, was discharged roughly six weeks after infusion, and is reported able to start vocational training.
- Clinicians warn the required high‑dose chemotherapy causes severe mucositis, risks liver injury and very likely sterilizes fertility, and the therapy carries conditional European approval with mandated 15‑year post‑treatment monitoring.
- Charité says it is the first qualified German center to offer the treatment but declined to disclose costs; reimbursement terms with insurers are confidential and published foreign list prices are around €1.87–1.91 million, raising questions about wider access and scalability.